Early detection of toxicity and adjustment of ongoing clinical trials: The history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program

Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Michelle R. Mahoney, James E. Krook, Michael J. O'Connell

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Prospective clinical trials are the gold standard for evidence-based methodology used to support changes in the practice of medicine. Clinical researchers, regulatory agencies, payers, and the public embrace the conduct of phase I, II, and III clinical trials as integral to improving patient care. The National Cancer Institute (NCI) funds a number of cooperative oncology groups to conduct such clinical trials in the United States. In order to protect enrolling patients, the NCI requires expedited reporting to allow rapid identification of severe side effects on NCI-sponsored clinical trials. However, chemotherapy drugs frequently cause predictable side effects, the rapid reporting of which would potentially overwhelm the system. This article describes the development and documents the performance of a real-time toxicity reporting system implemented by the North Central Cancer Treatment Group. The goal of this system is to supplement the currently required NCI adverse event monitoring procedures and to permit study teams to identify the need to modify ongoing clinical trials. The system has proven its value in the monitoring of phase II and III trials, including trial N9741, a three-arm, phase III, advanced colorectal cancer chemotherapy study exploring combinations of irinotecan, oxaliplatin, and fluorouracil. We believe the methods described present opportunities for improving patient safety in clinical research.

Original languageEnglish (US)
Pages (from-to)4591-4596
Number of pages6
JournalJournal of Clinical Oncology
Volume20
Issue number23
DOIs
StatePublished - Dec 1 2002

Fingerprint

National Cancer Institute (U.S.)
History
Clinical Trials
oxaliplatin
irinotecan
Neoplasms
Drug Therapy
Phase III Clinical Trials
Phase II Clinical Trials
Clinical Trials, Phase I
Financial Management
Therapeutics
Patient Safety
Fluorouracil
Colorectal Neoplasms
Patient Care
Research Personnel
Medicine
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Early detection of toxicity and adjustment of ongoing clinical trials : The history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. / Goldberg, Richard M.; Sargent, Daniel J.; Morton, Roscoe F.; Mahoney, Michelle R.; Krook, James E.; O'Connell, Michael J.

In: Journal of Clinical Oncology, Vol. 20, No. 23, 01.12.2002, p. 4591-4596.

Research output: Contribution to journalArticle

Goldberg, Richard M. ; Sargent, Daniel J. ; Morton, Roscoe F. ; Mahoney, Michelle R. ; Krook, James E. ; O'Connell, Michael J. / Early detection of toxicity and adjustment of ongoing clinical trials : The history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 23. pp. 4591-4596.
@article{237709ffda4e495ea18981dddd68d5ff,
title = "Early detection of toxicity and adjustment of ongoing clinical trials: The history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program",
abstract = "Prospective clinical trials are the gold standard for evidence-based methodology used to support changes in the practice of medicine. Clinical researchers, regulatory agencies, payers, and the public embrace the conduct of phase I, II, and III clinical trials as integral to improving patient care. The National Cancer Institute (NCI) funds a number of cooperative oncology groups to conduct such clinical trials in the United States. In order to protect enrolling patients, the NCI requires expedited reporting to allow rapid identification of severe side effects on NCI-sponsored clinical trials. However, chemotherapy drugs frequently cause predictable side effects, the rapid reporting of which would potentially overwhelm the system. This article describes the development and documents the performance of a real-time toxicity reporting system implemented by the North Central Cancer Treatment Group. The goal of this system is to supplement the currently required NCI adverse event monitoring procedures and to permit study teams to identify the need to modify ongoing clinical trials. The system has proven its value in the monitoring of phase II and III trials, including trial N9741, a three-arm, phase III, advanced colorectal cancer chemotherapy study exploring combinations of irinotecan, oxaliplatin, and fluorouracil. We believe the methods described present opportunities for improving patient safety in clinical research.",
author = "Goldberg, {Richard M.} and Sargent, {Daniel J.} and Morton, {Roscoe F.} and Mahoney, {Michelle R.} and Krook, {James E.} and O'Connell, {Michael J.}",
year = "2002",
month = "12",
day = "1",
doi = "10.1200/JCO.2002.03.039",
language = "English (US)",
volume = "20",
pages = "4591--4596",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "23",

}

TY - JOUR

T1 - Early detection of toxicity and adjustment of ongoing clinical trials

T2 - The history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program

AU - Goldberg, Richard M.

AU - Sargent, Daniel J.

AU - Morton, Roscoe F.

AU - Mahoney, Michelle R.

AU - Krook, James E.

AU - O'Connell, Michael J.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Prospective clinical trials are the gold standard for evidence-based methodology used to support changes in the practice of medicine. Clinical researchers, regulatory agencies, payers, and the public embrace the conduct of phase I, II, and III clinical trials as integral to improving patient care. The National Cancer Institute (NCI) funds a number of cooperative oncology groups to conduct such clinical trials in the United States. In order to protect enrolling patients, the NCI requires expedited reporting to allow rapid identification of severe side effects on NCI-sponsored clinical trials. However, chemotherapy drugs frequently cause predictable side effects, the rapid reporting of which would potentially overwhelm the system. This article describes the development and documents the performance of a real-time toxicity reporting system implemented by the North Central Cancer Treatment Group. The goal of this system is to supplement the currently required NCI adverse event monitoring procedures and to permit study teams to identify the need to modify ongoing clinical trials. The system has proven its value in the monitoring of phase II and III trials, including trial N9741, a three-arm, phase III, advanced colorectal cancer chemotherapy study exploring combinations of irinotecan, oxaliplatin, and fluorouracil. We believe the methods described present opportunities for improving patient safety in clinical research.

AB - Prospective clinical trials are the gold standard for evidence-based methodology used to support changes in the practice of medicine. Clinical researchers, regulatory agencies, payers, and the public embrace the conduct of phase I, II, and III clinical trials as integral to improving patient care. The National Cancer Institute (NCI) funds a number of cooperative oncology groups to conduct such clinical trials in the United States. In order to protect enrolling patients, the NCI requires expedited reporting to allow rapid identification of severe side effects on NCI-sponsored clinical trials. However, chemotherapy drugs frequently cause predictable side effects, the rapid reporting of which would potentially overwhelm the system. This article describes the development and documents the performance of a real-time toxicity reporting system implemented by the North Central Cancer Treatment Group. The goal of this system is to supplement the currently required NCI adverse event monitoring procedures and to permit study teams to identify the need to modify ongoing clinical trials. The system has proven its value in the monitoring of phase II and III trials, including trial N9741, a three-arm, phase III, advanced colorectal cancer chemotherapy study exploring combinations of irinotecan, oxaliplatin, and fluorouracil. We believe the methods described present opportunities for improving patient safety in clinical research.

UR - http://www.scopus.com/inward/record.url?scp=0036895122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036895122&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.03.039

DO - 10.1200/JCO.2002.03.039

M3 - Article

C2 - 12454117

AN - SCOPUS:0036895122

VL - 20

SP - 4591

EP - 4596

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 23

ER -